,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'breast', 'destiny-breast04']
3/3 moving fwd, we need to keep an eye on toxicities. higher rates of nausea &amp; 12% risk of pneumonitis noted on destiny-breast04. need to track rates of these and other toxicities in clinical settings. read more about the trial #asco22 #bcsm 
Mother of Warlords & Slayer of Cancers|Brst/Gyn #radonc @WeillCornell @nyphospital @nypbrooklyn | #globaloncology | #globalhealth|#MedEd|#gyncsm|#bcsm????????